LRRC40: A Potential Drug Target for Cancer (G55631)

Target Name: LRRC40

NCBI ID: G55631

LRRC40

LRRC40: A Potential Drug Target for Cancer

LRRC40 (LRC40_HUMAN) is a protein that is expressed in various tissues of the human body. It is a member of the long non-coding RNA (lncRNA) family and is characterized by its ability to interact with various transcription factors. LRRC40 has been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and the development of cancer. As a result, LRRC40 has gained significant interest as a potential drug target or biomarker.

The LRRC40 protein is composed of 214 amino acid residues and has a calculated molecular weight of 23.9 kDa. It is expressed in a variety of tissues, including muscle, liver, and brain, and has been shown to play a role in the development and progression of various diseases, including cancer.

One of the most significant functions of LRRC40 is its ability to interact with transcription factors. LRRC40 has been shown to form a complex with several transcription factors, including NF-kappa-B, AP-1, and SMAD3. These interactions allow LRRC40 to regulate the expression of target genes and are involved in the regulation of various cellular processes, including cell adhesion, migration, and the development of cancer.

LRRC40 has also been shown to play a role in the regulation of cellular signaling pathways. For example, LRRC40 has been shown to be involved in the regulation of the TGF-β pathway, a pathway that is involved in the regulation of cell growth, differentiation, and the development of cancer. LRRC40 has been shown to inhibit the activity of the transcription factor SMAD3, which is a key player in the TGF-β pathway, and to promote the activity of the transcription factor NF-kappa-B. These effects allow LRRC40 to regulate the expression of target genes that are involved in the TGF-β pathway, including genes that are involved in cell growth, differentiation, and the development of cancer.

LRRC40 has also been shown to play a role in the regulation of cellular apoptosis, a process that is involved in the programmed cell death that occurs in the development and treatment of cancer. LRRC40 has been shown to regulate the activity of the transcription factor p53, which is a key player in the regulation of apoptosis. These effects allow LRRC40 to regulate the expression of target genes that are involved in apoptosis, including genes that are involved in cell growth, differentiation, and the development of cancer.

In addition to its role in the regulation of cellular processes, LRRC40 has also been shown to play a role in the development and progression of various diseases, including cancer. For example, LRRC40 has been shown to be involved in the regulation of the growth and survival of cancer cells, as well as their migration and invasion. These effects allow LRRC40 to contribute to the development and progression of cancer, making it an attractive potential drug target or biomarker.

LRRC40 has also been shown to have potential clinical applications. For example, LRRC40 has been shown to be involved in the regulation of various cellular processes that are involved in the development and progression of cancer, including cell adhesion, migration, and the regulation of apoptosis. As a result, LRRC40 has been shown to have potential as a therapeutic agent for the treatment of various diseases, including cancer.

In conclusion, LRRC40 is a protein that has significant interest as a potential drug target or biomarker due to its ability to interact with various transcription factors and its role in the regulation of various cellular processes, including cell adhesion, migration, and the development

Protein Name: Leucine Rich Repeat Containing 40

The "LRRC40 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC40 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets